For all profiling needs, OncoHelix’ s exclusive test facility, HTL, uses validated and well-established panels from industry leading technology partners.
CGP Panels
OncoHelix-1
324 genes CGP Panel
CGP Assay uses the Roche AVENIO® Tumor Tissue CGP Kit, which leverages a secondary process, the FoundationOne® Analysis Platform.
The research use only assay was validated and its performance characteristics determined by OncoHelix. It has not been cleared or approved by Health Canada, as is the case for all solid tumor gene panels. The OncoHelix and HTL laboratories are certified to perform high-complexity testing. Any decisions related to patient care and treatment choices should be based on the independent judgement of the treating physician.
Learn more about the AVENIO® Tumor Tissue CGP Kit below
Small Variants (306): ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, ALOX12B, AMER1, APC, AR, ARAF, ARFRP1, ARID1A, ASXL1, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BCL2, BCL2L1, BCL2L2, BCL6, BCOR, BCORL1, BRAF, BRCA1, BRCA2, BRD4, BRIP1, BTG1, BTG2, BTK, C11orf30, CALR, CARD11, CASP8, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD22, CD274, CD70, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CHEK1, CHEK2, CIC, CREBBP, CRKL, CSF1R, CSF3R, CTCF, CTNNA1, CTNNB1, CUL3, CUL4A, CXCR4, CYP17A1, DAXX, DDR1, DDR2, DIS3, DNMT3A, DOT1L, EED, EGFR, EP300, EPHA3, EPHB1, EPHB4, ERBB2, ERBB3, ERBB4, ERCC4, ERG, ERRFI1, ESR1, EZH2, FAM46C, FANCA, FANCC, FANCG, FANCL, FAS, FBXW7, FGF10, FGF12, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR2, FGFR3, FGFR4, FH, FLCN, FLT3, FOXL2, FUBP1, GABRA6, GATA3, GATA4, GATA6, GID4 (C17orf39), GNA11, GNA13, GNAQ, GNAS, GRM3, GSK3B, H3F3A, HDAC1, HGF, HNF1A, HRAS, HSD3B1, ID3, IDH1, IDH2, IGF1R, IKBKE, IKZF1, INPP4B, IRF2, IRF4, IRS2, JAK1, JAK2, JAK3, JUN, KDM5A, KDM5C, KDM6A, KDR, KEAP1, KEL, KIT, KLHL6, KMT2A (MLL), KMT2D (MLL2), KRAS, LTK, LYN, MAF, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K13, MAPK1, MCL1, MDM2, MDM4, MED12, MEF2B, MEN1, MERTK, MET, MITF, MKNK1, MLH1, MPL, MRE11A, MSH2, MSH3, MSH6, MST1R, MTAP, MTOP, MUTYH, MYC, MYCL, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NFKBIA, NKX2-1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NT5C2, NTRK1, NTRK2, NTRK3, P2RY8, PALB2, PARK2, PARP1, PARP2, PARP3, PAX5, PBRM1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PDK1, PIK3C3B, PIK3C3G, PIK3CA, PIK3CB, PIK3R1, PIM1, PMS2, POLD1, POLE, PPARG, PPP2R1A, PPP2R2A, PRDM1, PRKAR1A, PRKCI, PTCH1, PTEN, PTPN11, PTPRO, QKI, RAC1, RAD21, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAF1, RARA, RB1, RBM10, REL, RET, RICTOR, RNF43, ROS1, RPTOR, SDHA, SDHB, SDHC, SDHD, SETD2, SF3B1, SGK1, SMAD2, SMAD4, SMARCA4, SMARCB1, SMO, SNCAIP, SOCS1, SOX2, SOX9, SPEN, SPOP, SRC, STAG2, STAT3, STK11, SYK, TBX3, TEK, TET2, TIPARP, TNFAIP3, TNFRSF14, TP53, TSC1, TSC2, TYRO3, U2AF1, VEGFA, VHL, WHSC1, WHSC1L1, WT1, XPO1, XRCC2, ZNF217, ZNF703
RNA Fusion (36): ALK, BCL2, BCR, BRAF, BRCA1, BRCA2, CD74, EGFR, ETV4, ETV5, ETV6, EWSR1, EZR, FGFR1, FGFR2, FGFR3, KIT, KMT2A (MLL), MSH2, MYB, MYC, NOTCH2, NTRK1, NTRK2, NUTM1, PDGFRA, RAF1, RARA, RET, ROS1, RSPO2, SDC4, SLC34A2, TERC, TERT, TMPRSS2
OncoHelix-2
170 genes CGP Panel
CGP Assay uses the Illumina TST-170 panel
The research use only assay was validated and its performance characteristics determined by OncoHelix. It has not been cleared or approved by Health Canada, as is the case for all solid tumor gene panels. The OncoHelix and HTL laboratories are certified to perform high-complexity testing. Any decisions related to patient care and treatment choices should be based on the independent judgement of the treating physician.
Specimen compatibility: Genomic DNA & RNA extracted from fresh frozen and FFPE tissues
DNA GENES:
Small variants and indel (148): AKT1, AKT2, AKT3, ALK, APC, AR, ARID1A, ATM, ATR, BAP1, BARD1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BRIP1, BTK, CARD11, CCND1, CCND2, CCNE1, CD79A, CD79B, CDH1, CDK12, CDK4, CDK6, CDKN2A, CEBPA, CHEK1, CHEK2, CREBBP, CSF1R, CTNNB1, DDR2, DNMT3A, EGFR, EP300, ERBB2, ERBB3, ERBB4, ERCC1, ERG, ESR1, EZH2, FAM175A, FANCI, FANCL, FBXW7, FGF1, FGF10, FGF2, FGF23, FGF3, FGF4, FGF5, FGF7, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT3, FOXL2, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, INPP4B, JAK2, JAK3, KDR, KIT, KRAS, MAP2K1, MAP2K2, MCL1, MDM2, MDM4, MET, MLH1, MLLT3, MPL, MRE11A, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCN, MYD88, NBN, NF1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NRG1, PALB2, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PMS2, PTCH1, PTEN, PTPN11, RAD51B, RAD51C, RAD54L, RB1, RET, RICTOR, ROS1, SLX4, SMAD4, SMARCB1, SMO, STK11, TET2, TP53, TSC1, TSC2
DNA amplification target genes (59): AKT2, ALK, AR, ATM, BRAF, BRCA1, BRCA2, CCND1, CCND3, CCNE1, CDK4, CDK6, CHEK1, CHEK2, EGFR, ERBB2, ERBB3, ERCC1, ERCC2, ESR1, FGF1, FGF10, FGF14, FGF19, FGF2, FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, JAK2, KIT, KRAS, LAMP1, MDM2, MDM4, MET, MYC, MYCL1, MYCN, NRAS, NRG1, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PTEN, RAF1, RET, RICTOR, RPS6KB1, TFRC
RNA GENES:
RNA fusion target genes (55): ABL1, AKT3, ALK, AR, AXL, BCL2, BRAF, BRCA1, BRCA2, CDK4, CSF1R, EGFR, EML4, ERBB2, ERG, ESR1, ETS1, ETV1, ETV4, ETV5, EWSR1, FGFR1, FGFR2, FGFR3, FGFR4, FLI1, FLT1, FLT3, JAK2, KDR, KIF5B, KIT, KMT2A (MLL), MET, MLLT3, MSH2, MYC, NOTCH1, NOTCH2, NOTCH3, NRG1, NTRK1, NTRK2, NTRK3, PAX3, PAX7, PDGFRA, PDGFRB, PIK3CA, PPARG, RAF1, RET, ROS1, RPS6KB1, TMPRSS2
OncoHelix-3
170 genes CGP Panel
CGP Assay uses the Illumina TST-170 panel (DNA only panel)
The research use only assay was validated and its performance characteristics determined by OncoHelix. It has not been cleared or approved by Health Canada, as is the case for all solid tumor gene panels. The OncoHelix and HTL laboratories are certified to perform high-complexity testing. Any decisions related to patient care and treatment choices should be based on the independent judgement of the treating physician.
Specimen compatibility: Genomic DNA extracted from fresh frozen and FFPE tissues
DNA GENES ALONE:
Small variants and indel (148): AKT1, AKT2, AKT3, ALK, APC, AR, ARID1A, ATM, ATR, BAP1, BARD1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BRIP1, BTK, CARD11, CCND1, CCND2, CCNE1, CD79A, CD79B, CDH1, CDK12, CDK4, CDK6, CDKN2A, CEBPA, CHEK1, CHEK2, CREBBP, CSF1R, CTNNB1, DDR2, DNMT3A, EGFR, EP300, ERBB2, ERBB3, ERBB4, ERCC1, ERG, ESR1, EZH2, FAM175A, FANCI, FANCL, FBXW7, FGF1, FGF10, FGF2, FGF23, FGF3, FGF4, FGF5, FGF7, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT3, FOXL2, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, INPP4B, JAK2, JAK3, KDR, KIT, KRAS, MAP2K1, MAP2K2, MCL1, MDM2, MDM4, MET, MLH1, MLLT3, MPL, MRE11A, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCN, MYD88, NBN, NF1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NRG1, PALB2, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PMS2, PTCH1, PTEN, PTPN11, RAD51B, RAD51C, RAD54L, RB1, RET, RICTOR, ROS1, SLX4, SMAD4, SMARCB1, SMO, STK11, TET2, TP53, TSC1, TSC2
DNA amplification target genes (59): AKT2, ALK, AR, ATM, BRAF, BRCA1, BRCA2, CCND1, CCND3, CCNE1, CDK4, CDK6, CHEK1, CHEK2, EGFR, ERBB2, ERBB3, ERCC1, ERCC2, ESR1, FGF1, FGF10, FGF14, FGF19, FGF2, FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, JAK2, KIT, KRAS, LAMP1, MDM2, MDM4, MET, MYC, MYCL1, MYCN, NRAS, NRG1, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PTEN, RAF1, RET, RICTOR, RPS6KB1, TFRC
OncoHelix-4 (CURRENTLY UNAVAILABLE)
38-gene ctDNA Panel
Assay uses FOLLOW IT® ctDNA Liquid Biopsy Focused Panel Powered by Canexia HealthTM Panel
The research use only assay was validated and its performance characteristics determined by OncoHelix. It has not been cleared or approved by Health Canada, as is the case for all solid tumor gene panels. The OncoHelix and HTL laboratories are certified to perform high-complexity testing. Any decisions related to patient care and treatment choices should be based on the independent judgement of the treating physician.
Specimen compatibility: Genomic DNA extracted from fresh blood sample
SNVs, deletions and insertions (up to 24bp):
AKT1: E17, ALK: T1151, L1152, C1156, F1174, L1196, L1198, G1202, D1203, S1206, G1269, R1275, Y1278 AR: L702H, V716, S741, W742, Q784, H875, F877, T878, M896 BRAF: Q201, G464, G466, F468, G469, Y472, D594, F595, G596, L597, V600, K601, part of Exon 15 (V600-M620), G606, CCNE: Amplification, CTNNB1: D32, S33, G34, I35, H36, S37, T41, S45, DDR2: L239, I638, S768, DICER1: D1705-D1709, G1809, D1810-E1813, EGFR: R108, A289, S492, P596, G598, Exon18, Exon19, Exon20, Exon21, & Amplification, ERBB2: G309, S310, K753, L755, I767, D769, Exon 20, & Amplification, ESR1: K303, E380, S463, V534, P535, L536, Y537, D538, FGFR1: N546, K656, & Amplification, FGFR2: S252, P253, W290, A315, S372, Y375, C382, N549, K659, E731, E777, & Amplification, FGFR3: R248, S249, G370, S371, Y373, G380, A391, 650, FOXL2: C134, GNA11: Q209, GNAQ: Q209, GNAS: R201, HRAS: G12, G13, Q61, IDH1: R132, IDH2: R140, R172, KIT: S476, Y553, W557 559, V560, L576, K642, V654, T670, D816, D820, N822, Y823, A829, Exon9, Exon11, Exon13, & Amplification, KRAS: K5, A11, G12, G13, L19, Q22, A59, G60, Q61, K117, A146, & Amplification, MAP2K1(MEK1): F53, Q56, K57, K59, V0, D67, I103, I111, C121, N122, P124, P387, MAP2K2(MEK2): F57, Q60, K61, L119, H123, G132, MET: T1010, V1112, H1112, G1181, L1213, D1246, Y1248, Y1253, Exon13, Exon 14 (-50 to +25), Exon18, & Amplification, NRAS: G12, G13, A59, G60, Q61, K117, A146, NTRK1: F589, G595, G667, NTRK3: G623, G696, PDGFRA: R560-E571, P577, N659, D842, L839-Y849, PIK3CA: R88, C90, R93, P104, G106, N107, R108, K111, R115, N345, R357, G364, E365, Exon6 [start to P377], C420, E453, P539, E542, E545, Q546, D549, E970, E978, M1043, N1044, A1046, H1047, G1049, & Amplification, POLE: Exon9, Exon10, Exon11, Exon12, Exon13, Exon14, (P286R, M295R, S297F, F367S, D368Y, V411L, L424I, M444K, A456P, S459F), PTCH1: W844, G1093, PTEN: A126, G129, R130, R173, R233, K254-K267, RET: G533, K603, C609, C611, C618, C620, C630, D631, C634, G691, E768, L790, Y791 V804, Y806, A886, S904, M918, A919, Exon10, Exon13, Exon15, ROS1: S1986, L2026, G2032, STK11: Q37, P281, TP53: Exon4, Exon5, Exon6, Exon7, Exon8, Exon9; MSI: 21Loci
Additional Panels
FOCUS Gene Panel for Solid Tumour such as Prostate, Bladder, Cholangiocarcinoma.
This panel is available on request for special projects.
Specimen compatibility: Genomic DNA and RNA extracted from fresh frozen and FFPE tissues
DNA amplification target genes: Small variants (133): AKT1, ALK, AR, BRAF, CDK4, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR2, FGFR3, GNA11, GNAQ, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS, PDGFRA, PIK3CA, RAF1, RET, ROS1, SMO; DNA amplification (59): ALK, AR, BRAF, CCND1, CDK4, CDK6, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, FGFR4, KIT, KRAS, MET, MYC, MYCN, PDGFRA, PIK3CA; RNA fusion (55): ABL1, ALK, AKT3, AXL, BRAF, EGFR, ERBB2, ERG, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK2, NTRK3, PDGFRA, PPARG, RAF1, RET, ROS1
Hematology Oncology Panel
This panel is available on request for special projects.
Myeloid (DNA) Panel